2001
DOI: 10.2174/0929867013371653
|View full text |Cite
|
Sign up to set email alerts
|

Quinolone, Everninomycin, Glycylcycline, Carbapenem, Lipopeptide and Cephem Antibacterials in Clinical Development

Abstract: The development of antibacterials was a very successful endeavor in the pharmaceutical company repertoire through the late 1970s, when interest in investing in antibiotic research and development temporarily waned. More recently, there have been a number of failures in late stage development or post-launch of human antibiotics. The answer to the dilemma of less-than-desired success may be the introduction of novel classes of agents, as well as development of new agents in traditional classes. This review provi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
22
0

Year Published

2009
2009
2017
2017

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 45 publications
(22 citation statements)
references
References 62 publications
0
22
0
Order By: Relevance
“…Furthermore, the rate of resistance to these drugs is higher in developing countries as compared to developed countries because of extensive and indiscriminate use of antibiotics over the last few decades [6] and people's ability to self-medicate without a prescription from a physician. Among the wide array of antibiotics, beta (β)-lactams are the most varied and widely used [7]. The most common cause of bacterial resistance to β-lactam antibiotics is the production of β-lactamases.…”
Section: Introductionmentioning
confidence: 99%
“…Furthermore, the rate of resistance to these drugs is higher in developing countries as compared to developed countries because of extensive and indiscriminate use of antibiotics over the last few decades [6] and people's ability to self-medicate without a prescription from a physician. Among the wide array of antibiotics, beta (β)-lactams are the most varied and widely used [7]. The most common cause of bacterial resistance to β-lactam antibiotics is the production of β-lactamases.…”
Section: Introductionmentioning
confidence: 99%
“…This emergence and spread of resistance are also threatening to create species resistant to all currently available agents. Approximately 20% of Klebsiella pnenumoniae infections and 31% of Enterobacter species infections in intensive care unit in the United States now involve strains not susceptible to 3rd-generation cephalosporins [2] Among the wide array of antibiotics, β-lactams are the most varied and widely used agents accounting for over 50% of all systemic antibiotics in use [3] . The most common cause of bacterial resistance to β-lactam antibiotics is the production of β-lactamases.…”
Section: Introductionmentioning
confidence: 99%
“…They include (a) natural products, (b) semisynthetic antibiotics and (c) synthetic chemicals [19]. The commercial antibiotics include the cephalosporins (45 %), penicillins (15 %), quinolones (11 %), tetracyclines (6 %), macrolides (5 %); the remainder include the aminoglycosides, ansamycins, glycopeptides, lipopeptides and polyenes.…”
Section: Antibioticsmentioning
confidence: 99%